About Us

At Cytovation, we are on a mission to make immunotherapy effective across a wide range of cancer types.

About
us

At Cytovation, we are on a mission to make immunotherapy effective across a wide range of cancer types.

Who We Are

Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital.

Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program has focused on engineering highly stable synthetic peptides with unique, antitumoral properties.

CY-101, the company’s lead candidate is being developed as a novel, first-in-class immunotherapy, that drives a tumor-specific immune response with a dual mode of action.

Management

Hoover over the image for more information

  • Lars Prestegarden, MD, PhD, is the co-founder and Chief Executive Officer (CEO) of Cytovation. Dr Prestegarden brings over 20 years of experience in cancer research. Before founding Cytovation, he conducted research at the University of California, San Francisco (UCSF) and was a Fulbright Fellow at Harvard Medical School and Brigham and Women’s Hospital. Following his fellowship, he held the position of Associate Professor of Medicine at the University of Bergen in Norway.

CEO

Lars Prestegarden

Lars Prestegarden, MD, PhD, is the co-founder and Chief Executive Officer (CEO) of Cytovation. Dr Prestegarden brings over 20 years of experience in cancer research. Before founding Cytovation, he conducted research at the University of California, San Francisco (UCSF) and was a Fulbright Fellow at Harvard Medical School and Brigham and Women’s Hospital. Following his fellowship, he held the position of Associate Professor of Medicine at the University of Bergen in Norway.

  • Federico has over 25 years of professional experience.  After 4 years in banking, at HSBC and Dresdner Bank, in 1999 he joined LETI Pharma, an allergy and immunology-focused biopharmaceutical company, where he held several commercial and general management roles. He joined Cytovation in 2016 to support the company’s strategic development and has gradually expanded his responsibilities to COO and CFO.  Federico has a BA in Economics from Tufts University, an MBA from IESE Business School, and an AMP Certificate from Harvard Business School.

COO/CFO

Federico Grego

Federico has over 25 years of professional experience. After 4 years in banking, at HSBC and Dresdner Bank, in 1999 he joined LETI Pharma, an allergy and immunology-focused biopharmaceutical company, where he held several commercial and general management roles. He joined Cytovation in 2016 to support the company’s strategic development and has gradually expanded his responsibilities to COO and CFO. Federico has a BA in Economics from Tufts University, an MBA from IESE Business School, and an AMP Certificate from Harvard Business School.

  • Diane is a Quality/Regulatory Affairs Professional with 30+ years of experience in regulatory, cGMP compliance, and quality systems. She has implemented quality systems, provided CMC regulatory submission strategy for EU, US dossiers, and has prepared modules 2 and 3 for INDs, IMPDs, NDAs and MAAs in eCTD format. She has also provided oversight for project technology transfer of manufacturing/analytical operations. Diane has been with Cytovation since 2018 providing support for CMC related activities. Diane has a BSC. (Hons.) degree majoring in Chemistry with Biology.

Regulatory and CMC Coordinator

Diane Cowie

Diane is a Quality/Regulatory Affairs Professional with 30+ years of experience in regulatory, cGMP compliance, and quality systems. In different positions held, she has implemented quality systems, provided CMC regulatory submission strategy for EU, US dossiers, and has prepared modules 2 and 3 for INDs, IMPDs, NDAs and MAAs in eCTD format. She has also provided oversight for project technology transfer of manufacturing/analytical operations. Diane has been with Cytovation since 2018 providing support for CMC related activities. Diane has a BSC. (Hons.) degree majoring in Chemistry with Biology.

  • Jeanette is a Registered Nurse with over 30 years of experience in the clinical research industry. She worked in various positions for hospitals, pharmaceutical and biotechnology companies as well as clinical research organizations. Her positions ranged from CRA, Clinical Project Manager, and Clinical Operations Manager to more Senior Management positions. She has experience in various therapeutic areas and over 10 years of experience in Oncology. Jeanette joined Cytovation in 2020 as Clinical Project Manager.

Clinical Project Manager

Jeanette Kamman

Jeanette is a Registered Nurse with over 30 years of experience in the clinical research industry. She worked in various positions for hospitals, pharmaceutical and biotechnology companies as well as clinical research organizations. Her positions ranged from CRA, Clinical Project Manager, and Clinical Operations Manager to more Senior Management positions. She has experience in various therapeutic areas and over 10 years of experience in Oncology. Jeanette joined Cytovation in 2020 as Clinical Project Manager.

Luft

  • Sandra has a MSc degree in Bio-Pharmaceutical Sciences. After working as a Medical Information Officer, she made the switch to clinical research in 1995. Since then, she has fulfilled various positions within clinical research through CROs and as a freelancer since 2009 onwards, such as CRA, Start-Up Specialist, Country Study Manager, Project Manager, Auditor and Science Office Staff Member. Her activities were within various therapeutic areas from phase 1 to phase 4 studies for industry, phase 1 units, biotech companies and hospitals. Sandra joined Cytovation in 2021 as Lead-CRA.

Lead CRA

Sandra Jansen

Sandra has a MSc degree in Bio-Pharmaceutical Sciences. After working as a Medical Information Officer, she made the switch to clinical research in 1995. Since then, she has fulfilled various positions within clinical research through CROs and as a freelancer since 2009 onwards, such as CRA, Start-Up Specialist, Country Study Manager, Project Manager, Auditor and Science Office Staff Member. Her activities were within various therapeutic areas from phase 1 to phase 4 studies for industry, phase 1 units, biotech companies and hospitals. Sandra joined Cytovation in 2021 as Lead-CRA.

  • Vetle Veiteberg has a BA in Economics and a Master’s degree in Auditing and Accounting from The Norwegian School of Economics (NHH). After graduating he joined PricewatherhouseCoopers for 4 years, where he worked and gained the title of State Authorized Auditor. Vetle joined Cytovation in 2022.

Deputy CFO

Vetle Veiteberg

Vetle Veiteberg has a BA in Economics and a Master’s degree in Auditing and Accounting from The Norwegian School of Economics (NHH). After graduating he joined PricewatherhouseCoopers for 4 years, where he worked and gained the title of State Authorized Auditor. Vetle joined Cytovation in 2022.

Board

Hoover over the image for more information

  • Stein Christian Mohn, MD PhD, has been on the Board of Cytovation ASA since 2017, and as Chair from 2021. He is the CEO and Chair of Mohn Drilling AS. Previously he worked as a doctor and molecular biologist at Haukeland University Hospital.

Chairman

Stein-Christian Mohn

Stein Christian Mohn, MD PhD, has been on the Board of Cytovation ASA since 2017, and as Chair from 2021. He is the CEO and Chair of Mohn Drilling AS. Previously he worked as a doctor and molecular biologist at Haukeland University Hospital.

  • Ellen has served as the Chief Business Officer of Werewolf Therapeutics since August 2020. From October 2018 to July 2020, Ms. Lubman served as the Chief Business Officer at Impel NeuroPharma, Inc., a publicly traded biotechnology company focused on neurological diseases. Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College.

Board Member

Ellen Lubman

Ellen has served as the Chief Business Officer of Werewolf Therapeutics since August 2020. From October 2018 to July 2020, Ms. Lubman served as the Chief Business Officer at Impel NeuroPharma, Inc., a publicly traded biotechnology company focused on neurological diseases. Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College.

  • Olav Hellebø is a board-level executive advising on clinical development and commercial readiness in oncology and immunology. He has been a public company CEO in cell therapy (ReNeuron) and oncology (Clavis Pharma) since 2010. Previously he held senior roles at UCB, Novartis, and Schering Plough (now Merck). Olav graduated in international business studies from Hofstra University, New York and earned an MBA from IESE, Barcelona.

Board Member

Olav Hellebø

Olav Hellebø is a board-level executive advising on clinical development and commercial readiness in oncology and immunology.
He has been a public company CEO in cell therapy (ReNeuron) and oncology (Clavis Pharma) since 2010. Previously he held senior roles at UCB, Novartis, and Schering Plough (now Merck). Olav graduated in international business studies from Hofstra University, New York and earned an MBA from IESE, Barcelona.

  • Martin brings over 30 years of experience in the life sciences sector, having spent a large part of his career at McKinsey & Company, where he co-led the global life sciences practice. His expertise spans global biopharma, medtech, genetics, and consumer health. Notably, Martin co-founded and led the McKinsey Health Institute, a non-profit entity focused on addressing fundamental health challenges. Martin holds a BA from Oxford University and an MBA from INSEAD.

Board Member

Martin Dewhurst

Martin brings over 30 years of experience in the life sciences sector, having spent a large part of his career at McKinsey & Company, where he co-led the global life sciences practice. His expertise spans global biopharma, medtech, genetics, and consumer health. Notably, Martin co-founded and led the McKinsey Health Institute, a non-profit entity focused on addressing fundamental health challenges. Martin holds a BA from Oxford University and an MBA from INSEAD.

Luft

  • Katherine brings extensive experience in healthcare investing, currently at Sandwater and previously at Hadean Ventures, including serving as a board observer for several biotech and health tech companies. Her background also includes healthcare investment banking at Goldman Sachs and corporate development at Theramex, giving her a well-rounded perspective across biotech growth and commercial strategy. She holds a degree in Bioengineering from UC Berkeley and an MBA from London Business School.

Board Member

Katherine Mellis

Katherine brings extensive experience in healthcare investing, currently at Sandwater and previously at Hadean Ventures, including serving as a board observer for several biotech and health tech companies. Her background also includes healthcare investment banking at Goldman Sachs and corporate development at Theramex, giving her a well-rounded perspective across biotech growth and commercial strategy. She holds a degree in Bioengineering from UC Berkeley and an MBA from London Business School.

Luft

Advisors

Rolf Bjerkvig

Ole-Erik Iversen

Bo Jesper Hansen

Raj Airey

© 2024 Cytovation ASA | All Rights Reserved
Webdesign by Limedrop

Terms & Conditions | Privacy & Cookies  | Code of Ethics 

© 2024 Cytovation ASA | All Rights Reserved | Webdesign by Limedrop
Terms & Conditions | Privacy & Cookies  | Code of Ethics

Cytovation AS